H pylori infection ond reflux oesophagitis [1]

Gut

Volumn 53, Issue 6, 2004, Pages 912-

  Kountouras, J ^a,b   Zavos, C ^a   Chatzopoulos, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

OMEPRAZOLE; TRIMEBUTINE;

ANTIBIOTIC THERAPY; COMORBIDITY; DISEASE ASSOCIATION; DRUG INDICATION; FOLLOW UP; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; INFECTION CONTROL; IRRITABLE COLON; LETTER; MONOTHERAPY; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

COHORT STUDIES; DRUG THERAPY, COMBINATION; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRRITABLE BOWEL SYNDROME; OMEPRAZOLE; TRIMEBUTINE;

EID: 2442644988     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Schwizer W, Thumshirn M, Dent J, et al. Helicobocter pylori and symptomatic relapse of gastro-oesopnageal reflux disease: a randomised controlled trial. Lancet 2001;357:1738-42.
2. Kountouros J, Chatzopoulos D, Zavos C, et al. Efficacy of trimebutine therapy in patients with gastroesophageal reflux disease and irritable bowel syndrome. Hepatogastroenterology 2002;49:193-7.
3. Pimentel M, Rossi F, Chow EJ, et al. Increased prevalence of irritable bowel syndrome in patients with gastroesophageal reflux. J Clin Gastroenterol 2002;34:221-4.
4. O'Connor HJO, McGee C, Mehana N, et al. Prevalence of gastroesophageal reflux disease (GERD) in H. pylori-positive peptic ulcer disease and the impact of eradication therapy. Gastroenterology 1998;114:G1001.
5. Ecclissato C, Carvalho AF, Ferraz JG, et al. Prevalence of peptic lesions in asymptomatic, healthy volunteers. Dig Liver Dis 2001;33:403-6.